Business Description
Definium Therapeutics, based in New York, is a clinical-stage company focused on developing new treatments for mental health and brain-related conditions. Its most advanced drug, DT120, is currently in Phase 3 trials for generalized anxiety disorder and major depression, while a second compound, DT402, is in earlier trials targeting autism spectrum disorder. The company was previously called Mind Medicine (MindMed) before adopting its current name in January 2026.
